738
Participants
Start Date
April 30, 2006
Primary Completion Date
May 31, 2007
Study Completion Date
March 31, 2008
Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate
Escalating doses, 6 weekly subcutaneous (under the skin) injections
Histamine base
Escalating doses, 6 weekly subcutaneous (under the skin) injections
Asthma & Allergy Research Associates, Upland
Allergy & Asthma Center, High Point
Atlanta Allergy & Asthma Clinic, Stockbridge
Clinical Research of Atlanta, Stockbridge
Center Of Research Excellence, Oxford
Allergy & Respiratory Center, Canton
Bernstein Clinical Research Center, Cincinnati
Research Center of Indiana, Indianapolis
Advanced Healthcare, Milwaukee
Asthma, Allergy & Sinus Center, Greenfield
University of Wisconsin Madison Medical School, Madison
Asthma and Allergy Research Center, Minneapolis
Clinical Research Institute, Plymouth
Sneeze, Wheeze, and Itch Associates, Normal
Clinical Research Center, St Louis
Clinical Research of the Ozarks, Warrensburg
Clinical Research of the Ozarks, Columbia
Clinical Research of The Ozarks, Rolla
Asthma & Allergy Center, Papillion
Midwest Allergy & Asthma Clinic, Omaha
Creighton University, Omaha
Allergy, Asthma and Clinical Research Center, Oklahoma City
AARA Research Center, Dallas
Pharmaceutical Research & Consulting, Dallas
Kerrville Allergy and Asthma Associates, Kerrville
Central Texas Health Research, New Braunfels
Sylvana Research, San Antonio
Princeton Center for Clinical Research, Skillman
Lead Sponsor
Dynavax Technologies Corporation
INDUSTRY